Haemonetics downgraded to Hold from Buy at Needham

Needham downgraded Haemonetics (HAE) to Hold from Buy without a price target The firm’s checks indicate rising concern around competition for Haemonetics’ vascular closure devices, as Abbott (ABT) and Cordis introduce newer venous closure products supported by dedicated electrophysiology sales teams, the analyst tells investors in a research note. Although stronger Plasma and Blood Management Technologies growth may offset weakness in FY26, sustained declines in Interventional Technologies are expected to constrain FY27 revenue and EPS growth and put consensus estimates at risk, the firm says.